Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy

Anti-Cancer Drugs

Volumn 22, Issue 9, 2011, Pages 864-874

  Kim, Hyunki ^a,b,f   Zhai, Guihua ^a   Liu, Zhiyong ^c   Samuel, Sharon ^a   Shah, Nemil ^d   Helman, Emily E ^c   Knowles, Joseph A ^c   Stockard, Cecil R ^e   Fineberg, Naomi S ^f   Grizzle, William E ^e,f   Zhou, Tong ^d,f   Zinn, Kurt R ^a,d,f   Rosenthal, Eben L ^c,f  

^a University of Alabama at Birmingham   (United States)

^b and Radiation Oncology   (United States)

^c Kentucky   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

extracellular matrix metalloproteinase; pancreatic cancer; targeted therapy

Indexed keywords

1 A 6; ANTINEOPLASTIC AGENT; CNTO 3899; EXTRACELLUAR MATRIX METALLOPROTEINASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 KAPPA; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CELL DENSITY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG TARGETING; ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LONGITUDINAL STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOTOPIC TRANSPLANTATION; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD147; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KI-67 ANTIGEN; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, SCID; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RADIOIMMUNOASSAY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052532390     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328349311e     Document Type: Article

References (53)

1. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005; 128:1626-1641 (Pubitemid 40692556)
2. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413 (Pubitemid 27251144)
3. Loehrer PJ, Powell ME, Cardenes HR,Wagner L, Brell JM, Ramanathan RK, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 J Clin Oncol 2008; 26: (Suppl):4506
4. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 2002; 20:3270-3275 (Pubitemid 34831525)
5. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952 (Pubitemid 46630743)
6. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22:3776-3783 (Pubitemid 41095218)
7. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, AndréT, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-3516
8. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX [F: 5FU/leucovorin (LV), irinotecan (I), and oxaliplatin (O)] versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010; 28:15s.
9. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W,Wolff RA, Deutsch J, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22:2610-2616 (Pubitemid 41103748)
10. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23:8033-8040. (Pubitemid 46657405)
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966 (Pubitemid 46972777)
12. Riethdorf S, Reimers N, Assmann V, McCabe F, Millar H, Rafferty P, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006; 119:1800-1810. (Pubitemid 44356836)
13. Rosenthal EL, Vidrine DM, Zhang W, Kornfeld JW, Terracciano L, Sauter G, et al. Extracellular matrix metalloprotease inducer stimulates fibroblastmediated tumor growth in vivo. Laryngoscope 2006; 116:1086-1092 (Pubitemid 44334750)
14. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65:3193-3199 (Pubitemid 40524601)
15. Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblastderived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006; 6:52
16. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002; 19:697-702 (Pubitemid 36092265)
17. Braundmeier AG, Fazleabas AT, Lessey BA, Guo H, Toole BP, Nowak RA. Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium. J Clin Endocrinol Metab 2006; 91:2358-2365 (Pubitemid 43855028)
18. Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M, Gelatinase A. Membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 2000; 24:334-340. (Pubitemid 30117763)
19. Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, et al.Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 2001; 158:1921-1928 (Pubitemid 32545174)
20. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 2000; 85:14-20.
21. Quemener C, Gabison EE, Naimi B, Lescaille G, Bougatef F, Podgorniak MP, et al. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007; 67:9-15 (Pubitemid 46142753)
22. Bougatef F, Quemener C, Kellouche S, Naimi B, Podgorniak MP, Millot G, et al. EMMPRIN promotes angiogenesis through hypoxia-inducible factor- 2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2 Blood 2009; 114:5547-5556
23. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10:3422-3428 (Pubitemid 38685448)
24. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res 1994; 54:2761-2764 (Pubitemid 24173771)
25. Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Bucholz M, et al. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 2009; 58:1391-1398
26. Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, et al. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 2009; 15:4058-4065
27. Dean NR, Knowles JA, Helman EE, Aldridge JC, Carroll WR, Magnuson JS, et al. Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anti-cancer Drugs 2010; 21:861-867
28. Pezold JC, Zinn K, Talbert MA, Desmond R, Rosenthal EL. Validation of ultrasonography to evaluate murine orthotopic oral cavity tumors. ORL J Otorhinolaryngol Relat Spec 2006; 68:159-163
29. Derosier LC, Buchsbaum DJ, Oliver PG, Huang Z, Sellers JC, Grizzle WE, et al. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007; 13:5535s-5543s. (Pubitemid 47510384)
30. Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007; 6:3198-3207
31. Haider MA, Van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189:323-328 (Pubitemid 47195916)
32. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92:2029-2036 (Pubitemid 32045900)
33. Moffat BA, Chenevert TL, Meyer CR, Mckeever PE, Hall DE, Hoff BA, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006; 8:259-267
34. Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 2005; 4:35-42
35. Kartalis N, Lindholm TL, Aspelin P, Permert J, Albiin N. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol 2009; 19:1981-1990.
36. Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE,Warram JM, et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008; 68:8369-8376
37. Larsen SK, Solomon HF, Caldwell G, Abrams MJ. [99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem 1995; 6:635-638
38. Lowry O, Rosebrough N, Farr L, Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275
39. Motulsky HJ, Christopoulos A. Fitting models to biological data using linear and nonlinear regression. San Diego: GraphPad Software Inc.; 2003
40. Winzor DJ, Sawyer WH. Quantitative characterization of ligand binding. New York: Wiley-Liss; 1995
41. Kim H, Morgan DE, Zeng H, Grizzle WE, Warram JM, Stockard CR, et al. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 2008; 248:844-851
42. Kim H, Folks KD, Guo L, Stockard CR, Fineberg NS, GrizzleWE, et al. DCEMRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol 2011; 13:94-103
43. Neter J, Kutner MH, Nachtsheim JC,WassermanW. Applied linear statistical models. Columbus: The McGraw-Hill Companies, Inc.; 1996
44. Hertzog C, Rovine M. Repeated-measures analysis of variance in developmental research: selected issues. Child Dev 1985; 56:787-809
45. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of bim. J Biol Chem 2006; 281:9719-9727 (Pubitemid 43864690)
46. Bougatef F, Menashi S, Khayati F, Naimi B, Porcher R, Podgorniak MP, et al. EMMPRIN promotes melanoma cells malignant properties through a HIF- 2alpha mediated up-regulation of VEGF-receptor-2 PLoS One 2010; 5:e12265
47. Kim H, Folks K, Guo L, Sellers JC, Fineberg NS, Stockard CR, et al. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Mol Imaging 2011; 10:153-167
48. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004; 40:802-820. (Pubitemid 38519759)
49. Escorcia FE, Henke E, McDevitt MR, Villa CH, Jones PS, Blasberg RG, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010; 70:9277-9286
50. Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, Rustum YM. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008; 14:3926-3932
51. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-960. (Pubitemid 32756434)
52. Rajeshkumar NV, Rasheed Z, Garcia-Garcia E, López-Ríos F, Fujiwara K, Matsui WH, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9:2582-2592
53. Fenster A, Downey DB. Cardinal HN three-dimensional ultrasound imaging. Phys Med Biol 2001; 46:R67-R99